Intuitive Surgical ISRG delivered a strong capital performance in the first quarter of 2026. The company placed 431 da Vinci systems during the quarter, up 17% year over year, signaling continued robust demand for robotic-assisted surgery. The growth is being driven by the accelerating adoption of the da Vinci 5 platform, which accounted for 232 placements during the quarter. However, a closer look suggests that a significant portion of the surge may be driven by an ongoing upgrade cycle rather than by pure new-market expansion.
One important indicator is the sharp increase in trade-in activity. Intuitive Surgical reported 119 trade-in transactions in the first quarter compared with 67 a year earlier, primarily driven by U.S. hospitals replacing older systems with da Vinci 5. This suggests that existing customers are refreshing installed systems to access new capabilities such as force feedback technology, higher throughput and expanding digital integration.
While these factors should drive near-term system sales, elevated upgrade-driven demand raises questions around how sustainable current placement growth will remain once the replacement cycle normalizes.
Another notable trend is the rising adoption of leasing. Leasing represented 56% of da Vinci placements, up from 47% in the prior quarter, reflecting growing customer preference for more flexible capital spending models amid uncertain hospital budgets. Leasing revenues also grew 28%, supported by higher utilization and a greater mix of premium-priced da Vinci 5 systems.
The key debate for investors is whether current capital demand is cyclical or structural. While the elevated trade-in cycle may moderate over time, management continues to point toward structural demand drivers, including 17% procedure growth, rising utilization, expanding international adoption and higher recurring revenues now representing 86% of total sales.
This suggests that although upgrade activity is boosting near-term placements, the broader long-term demand profile for Intuitive Surgical’s robotic ecosystem remains fundamentally strong. Even if capital placement softens after the upgrade cycle peaks, the higher utilization rate of da Vinci 5 should continue to boost higher-margin recurring revenues.
Peer Updates
Globus Medical GMED delivered strong capital equipment momentum in the first quarter of 2026, with its Enabling Technologies segment growing 21.1% year over year to $26.9 million, reflecting healthy demand for the company’s ExcelsiusGPS robotic platform. Management highlighted a robust pipeline and stronger deal conversions compared with the softer prior-year quarter.
The growth is increasingly being driven by a strategic shift toward leasing and rental agreements rather than outright cash sales, providing hospitals with greater capital flexibility amid tighter spending environments. Beyond direct system sales, management emphasized that robotics placements are increasingly serving as a catalyst for higher-margin recurring revenue streams, including implants, disposables, service contracts and procedural pull-through, reinforcing long-term ecosystem expansion.
Stereotaxis STXS remains in the early stages of rebuilding its capital equipment business, with first-quarter 2026 system revenues declining to $1.3 million from $2 million a year ago, reflecting a temporary transition period rather than weakening demand. Growth is expected to accelerate as the company rolls out GenesisX, its next-generation robotic platform that eliminates the need for construction-heavy catheter lab modifications, significantly broadening adoption potential.
Management indicated a healthy pipeline of physicians and hospitals moving toward orders, with expectations to establish at least five active GenesisX programs in 2026. Additional momentum is being supported by the commercial launch of Synchrony, the company’s digital surgery cockpit, which has already secured multiple early orders and is expected to contribute $3 million in 2026 revenues.
ISRG’s Price Performance, Valuation and Estimates
Shares of ISRG have lost 27.5% so far this year compared with a 17.6% decline for the industry.
Image Source: Zacks Investment Research
From a valuation standpoint, Intuitive Surgical trades at a forward price-to-earnings ratio of 37.39, above the industry average. But, it is still lower than its five-year median of 70.02. ISRG carries a Value Score of D.
Image Source: Zacks Investment Research
The Zacks Consensus Estimate for Intuitive Surgical’s 2026 earnings implies a 16.5% rise from the year-ago period’s level.
Image Source: Zacks Investment Research
The stock currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Zacks' Research Chief Names "Stock Most Likely to Double"
Our team of experts has just released the 5 stocks with the greatest probability of gaining +100% or more in the coming months. Of those 5, Director of Research Sheraz Mian highlights the one stock set to climb highest.
This top pick is a little-known satellite-based communications firm. Space is projected to become a trillion dollar industry, and this company's customer base is growing fast. Analysts have forecasted a major revenue breakout in 2025. Of course, all our elite picks aren't winners but this one could far surpass earlier Zacks' Stocks Set to Double like Hims & Hers Health, which shot up +209%.
Free: See Our Top Stock And 4 Runners UpWant the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Intuitive Surgical, Inc. (ISRG): Free Stock Analysis Report
Stereotaxis Inc. (STXS): Free Stock Analysis Report
Globus Medical, Inc. (GMED): Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).